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Summary of findings {#CD009818-sec1-0001}
===================

###### \'Summary of findings\' table 1

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- -------------------------------------- ----------------------------------------- ----------------------- --------------------------------------------------------------
  **Interleukin‐2 compared to control for HIV‐positive adults**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  **Patient or population:** HIV‐positive adults  **Settings:** high‐ and middle‐income settings  **Intervention:** interleukin‐2 (IL‐2) plus antiretroviral therapy (ART)  **Comparison:** ART alone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Illustrative comparative risks\* (95% CI)**   **Relative effect  (95% CI)**     **Number of participants  (trials)**   **Certainty of the evidence  (GRADE)**    **Comments**            

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  **Corresponding risk**                                                                                                                                                                     

  **Control**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **IL‐2**                                                                                                                                                                                   

  All‐cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **60 per 1000**                                 **58 per 1000**   (48 to 70)      **RR 0.97**   (0.80 to 1.17)           6565  (6 trials)                          ⊕⊕⊕⊕  **high**          There is little or no effect on all cause mortality

  CD4 cell count                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Tended to increase in all but one study         7600\                             ---                                    Tended to increase in all but one study                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (21 trials)                                                                                                                                

  HIV RNA levels less than 50 cells/mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              **636 per 1000**                                **617 per 1000**   (515 to 732)   **RR 0.97**   (0.81 to 1.15)           805  (5 trials)                           ⊕⊕⊕⊕  **high**          There is little or no effect on viral suppression

  HIV RNA levels less than 500 cells/mL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **81 per 1000**                                 **77 per 1000**   (66 to 90)      **RR 0.96**   (0.82 to 1.12)           5929  (4 trials)                          ⊕⊕⊕⊕  **high**          

  Opportunistic infections                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **46 per 1000**                                 **39 per 1000**   (26 to 54)      **RR 0.79**   (0.55 to 1.13)           6141  (7 trials)                          ⊕⊕⊝⊝  **low^1^**        There may be little or no effect on opportunistic infections

  Adverse events (grade 3 or 4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     **197 per 1000**                                **242 per 1000**   (193 to 303)   **RR 1.47**   (1.10 to 1.96)           6291  (6 trials)                          ⊕⊕⊕⊝  **moderate^2^**   There is probably an increase in adverse events

  \*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  **Abbreviations:** CI: confidence interval; RR: risk ratio.                                                                                                                                                                                                                                                                                                                                                                                               

  GRADE Working Group grades of evidence  **High certainty:** further research is very unlikely to change our confidence in the estimate of effect.  **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.  **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.  **Very low certainty:** we are very uncertain about the estimate.                                                                                                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- -------------------------------------- ----------------------------------------- ----------------------- --------------------------------------------------------------

^1^Downgraded by 2 for imprecision due to low event rate resulting in a wide 95% CI is wide. The overall meta‐analysis remains underpowered to confidently exclude effects.  ^2^Downgraded by 1 for imprecision.

Background {#CD009818-sec1-0002}
==========

Description of the condition {#CD009818-sec2-0001}
----------------------------

Human immunodeficiency virus (HIV) continues to be a major cause of morbidity and mortality globally ([UNAIDS 2016](#CD009818-bbs2-0051){ref-type="ref-list"}). In 2015 there were 2.1 million people newly diagnosed as HIV‐positive with almost half of those from Southern and Eastern Africa ([UNAIDS 2016](#CD009818-bbs2-0051){ref-type="ref-list"}). In addition to the decrease in life expectancy caused by the disease, there are substantial health costs that may impact on the economy of affected countries. This has all led to strategic efforts by world leaders and researchers to discover effective treatments for the condition and thus curtail loss of life and the related social and economic burden ([UNAIDS 2016](#CD009818-bbs2-0051){ref-type="ref-list"}).

HIV harms the body\'s immune system, particularly the CD4 lymphocytes. It destroys the host immune system, making it susceptible to opportunistic infections ([Grimwade 2009](#CD009818-bbs2-0040){ref-type="ref-list"}; [Harari 2004](#CD009818-bbs2-0042){ref-type="ref-list"}). Though various interventions have helped to improve the quality of life and life expectancy of HIV‐positive individuals, interventions are needed that will alleviate the effects of the disease by restoring the immune system ([Harari 2004](#CD009818-bbs2-0042){ref-type="ref-list"}). For instance, following the introduction of antiretroviral therapy (ART) including at least three antiretroviral agents, the treatment of HIV infection is highly potent and fairly well tolerated but not without limitations ([Nachega 2011](#CD009818-bbs2-0047){ref-type="ref-list"}). ART, which is currently the mainstay of treatment, inhibits viral replication and does not reconstitute the immune system directly ([Blankson 2000](#CD009818-bbs2-0037){ref-type="ref-list"}; [Piliero 2003](#CD009818-bbs2-0049){ref-type="ref-list"}). Many HIV‐positive adults do not achieve normal CD4 counts despite suppressing viral replication ([Pett 2010](#CD009818-bbs2-0048){ref-type="ref-list"}).

Long‐term ART use is associated with drug‐resistant HIV strains, as well as cumulative drug‐related toxicities, including abnormalities in substrate metabolism ([Piliero 2003](#CD009818-bbs2-0049){ref-type="ref-list"}). In addition, prolonged ART exposure may result in adherence fatigue and increased morbidity. This has encouraged the exploration of novel strategies to reduce the infection by augmenting the immune system and if possible completely reconstituting the immune system ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}). One such novel potential strategy has been the use of interleukin‐2 (IL‐2) as an adjunct with ART ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}).

Description of the intervention {#CD009818-sec2-0002}
-------------------------------

IL‐2 is a cytokine that regulates the proliferation and differentiation of lymphocytes. Cytokines are immunological proteins produced by lymphocytes which work to expand the pool of immunological cells and mobilize latent reservoirs of such cells in people with HIV and other infections ([Pett 2001](#CD009818-bbs2-0033){ref-type="ref-list"}). IL‐2 is a T‐cell growth factor produced predominantly by CD4+ T‐cells([Pett 2001](#CD009818-bbs2-0033){ref-type="ref-list"}). Its production is decreased in HIV‐positive participants ([Abrams 2009](#CD009818-bbs2-0036){ref-type="ref-list"}). A synthetic version of the protein has been produced as proleukin. It is an important factor in the proliferation of CD4 T lymphocytes, which is a major target of HIV ([Pett 2010](#CD009818-bbs2-0048){ref-type="ref-list"}). It is also useful in the differentiation of CD4 and CD8 cells, natural killer cells, and macrophages ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}). These cells are depleted in HIV‐positive participants, and therefore there has been this interest in the use of IL‐2 as an adjuvant therapy in the treatment of HIV‐positive individuals ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}). The low dose formulation of proleukin is rarely known to cause side effects and appears to be well‐tolerated ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}). Earlier studies reported that, by helping the reconstitution of the immune system, IL‐2 may help to defer the commencement of ART in certain participants by up to 48 weeks ([Molina 2007](#CD009818-bbs2-0046){ref-type="ref-list"}). However, little is known about its interaction with ART and the potential toxicities in adults, children, and unborn babies ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}).

How the intervention might work {#CD009818-sec2-0003}
-------------------------------

IL‐2 may work by increasing the CD4 cell count and therefore assisting to reconstitute the immune system, and help in the control of viral replication thereby boosting the effect of ART ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}). By priming the immune system it might help protect it from the damage caused by HIV and lead to lower susceptibility to opportunistic infections ([Horn 2002](#CD009818-bbs2-0045){ref-type="ref-list"}).

Why it is important to do this review {#CD009818-sec2-0004}
-------------------------------------

If there is proven benefit of using IL‐2 as an adjunct in terms of decreased viral load and adverse effects, increased CD4 counts, and other patient‐related important outcomes, there will be value in introducing the use of IL‐2 more systematically as a treatment adjunct aiming for an overall improvement in morbidity and mortality. This review aims to summarize the available evidence from randomized controlled trials (RCTs) on the use of IL‐2 as an adjunct to ART in the treatment of HIV‐positive participants.

Objectives {#CD009818-sec1-0003}
==========

To assess the effects of interleukin‐2 (IL‐2) as an adjunct to antiretroviral therapy (ART) for HIV‐positive adults.

Methods {#CD009818-sec1-0004}
=======

Criteria for considering studies for this review {#CD009818-sec2-0005}
------------------------------------------------

### Types of studies {#CD009818-sec3-0001}

Randomized controlled trials (RCTs).

### Types of participants {#CD009818-sec3-0002}

Adults who were 18 years old and above, diagnosed as seropositive for HIV on finger prick or laboratory blood testing and eligible to receive antiretroviral treatment (ART).

These included ART‐naive (no prior ART exposure) and ART‐experienced (previously treated or currently on ART) participants. The safety of interleukin‐2 (IL‐2) in children is not yet proven.

### Types of interventions {#CD009818-sec3-0003}

IL‐2 and any combination of ART.

Variations of interest included IL‐2 co‐administered with antiretroviral monotherapy or with dual therapy or with the standard recommended three drug regimens.

We included any dose of IL‐2 for this review.

### Types of outcome measures {#CD009818-sec3-0004}

#### Primary outcomes {#CD009818-sec4-0001}

All‐cause mortality.

#### Secondary outcomes {#CD009818-sec4-0002}

Change in CD4 cell count.Proportion of participants with undetectable viral load at any time point after initiation of IL‐2.Opportunistic infections.Adherence (as measured by the trial authors).Adverse events.

Search methods for identification of studies {#CD009818-sec2-0006}
--------------------------------------------

### Electronic searches {#CD009818-sec3-0005}

We formulated a comprehensive and exhaustive search strategy in order to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress).

#### Journals and trial databases {#CD009818-sec4-0003}

We searched the following electronic databases from 1980 up to 26 May 2016.

The Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library ([Appendix 1](#CD009818-sec2-0016){ref-type="app"}).MEDLINE ([Appendix 2](#CD009818-sec2-0017){ref-type="app"}).Embase ([Appendix 3](#CD009818-sec2-0018){ref-type="app"}).

Along with MeSH terms and relevant keywords, we used the Cochrane Highly Sensitive Search Strategy for identifying reports of RCTs in MEDLINE ([Higgins 2008a](#CD009818-bbs2-0043){ref-type="ref-list"}). We also searched references of included studies for other potentially relevant studies. Using a variety of relevant terms, we also searched ClinicalTrials.gov ([www.clinicaltrials.gov](www.clinicaltrials.gov); [Appendix 4](#CD009818-sec2-0019){ref-type="app"}) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<http://apps.who.int/trialsearch/>) for any ongoing trials.

### Searching other resources {#CD009818-sec3-0006}

#### Conference abstract databases {#CD009818-sec4-0004}

We planned to search Aegis archive of HIV/AIDS conference abstracts ([www.aegis.org](www.aegis.org)). However, this database is no longer functional and was not searched.

We did search the CROI and International AIDS Society websites for abstracts presented at conferences subsequent to those listed above using different combinations of relevant search terms, such as antiretroviral, interleukin‐2, HIV, viral load, therapy, CD4 count, and other terms in combination. We contacted experts and relevant organizations in the field to identify any other potentially eligible studies, including unpublished and ongoing trials.

Data collection and analysis {#CD009818-sec2-0007}
----------------------------

### Selection of studies {#CD009818-sec3-0007}

Two review authors (JO and CO) independently screened the titles and abstracts of the literature search results to identify potentially eligible studies. We resolved any discrepancies through discussion. We obtained the full‐text articles of all potentially eligible articles in order to formally assess eligibility using the prespecified eligibility criteria. If there was ambiguity we sought clarification from the study authors. We listed all excluded studies and their reasons for exclusion in a \'Characteristics of excluded studies\' table. We also presented the study selection process in a PRISMA diagram.

### Data extraction and management {#CD009818-sec3-0008}

Two review authors (JO and CO) independently extracted data from the included trials using a detailed data extraction form. We extracted the following information.

Study details: citation, start and end dates, location, study design, and details.Participant details: study population eligibility (inclusion and exclusion) criteria, ages, population size, and attrition rate.Details about the interventions: dose, duration of treatment, concomitant antiretroviral treatment (ART) regimens.Details of the outcomes: CD4 cell count, viral load, death, adverse effects, and adherence.

For each dichotomous outcome, we extracted the number of participants experiencing the event and the number of participants in each treatment group. For each continuous outcome we extracted the mean or geometric mean values and standard deviations (SDs) (or information to estimate the SDs) for each treatment group, together with the numbers of participants in each group. We also extracted the median and range values if these were reported in place of mean and SDs values.

### Assessment of risk of bias in included studies {#CD009818-sec3-0009}

Two review authors (JO and CO) performed the \'Risk of bias\' assessments independently using the Cochrane \'Risk of bias\' assessment tool ([Higgins 2008b](#CD009818-bbs2-0044){ref-type="ref-list"}). The Cochrane approach assesses risk of bias in individual studies across the following six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential biases.

We resolved any differences in opinion through discussion. We presented the \'Risk of bias\' assessments for individual trials in the \'Risk of bias\' tables, and also in a \'Risk of bias\' summary and \'Risk of bias\' graph.

### Measures of treatment effect {#CD009818-sec3-0010}

For dichotomous outcomes, we used risk ratios (RRs) to measure treatment effect. For continuous outcomes, we presented the mean or median and SD values or ranges. We presented RRs and mean differences with 95% confidence intervals (CIs).

### Unit of analysis issues {#CD009818-sec3-0011}

All included trials were RCTs and we analysed the data at the level of the individual.

### Dealing with missing data {#CD009818-sec3-0012}

We did not apply any imputation measures for missing data as there were no missing data. we planned to contact authors for missing data, but this was not required.

### Assessment of heterogeneity {#CD009818-sec3-0013}

We assessed statistical heterogeneity by visually inspecting the forest plots to detect overlapping confidence intervals, applying the Chi^2^ test (P value \< 0.10 considered statistically significant), and also by using the I^2^ test statistic to evaluate the degree of heterogeneity.

### Assessment of reporting biases {#CD009818-sec3-0014}

Funnel plots describe the relationship between the standard error and the effect size and provide a graphic display of potential reporting bias. We had planned to evaluate reporting bias by assessing the symmetry of a funnel plot. However, as the recommended 10 study minimum was not met for any of the outcomes, we did not proceed with the funnel plot assessment.

### Data synthesis {#CD009818-sec3-0015}

We analysed data using Review Manager 5 (RevMan 5) software ([Review Manager 5](#CD009818-bbs2-0050){ref-type="ref-list"}), and conducted meta‐analysis using the random‐effects model. We assessed the certainty of the evidence across each outcome measure by using the GRADE approach. The certainty rating across studies has four levels: high, moderate, low, or very low certainty but can be downgraded after assessment of five criteria: risk of bias, consistency, indirectness, imprecision, and publication bias. Similarly, observational studies are initially categorized as low certainty and can be downgraded by these same criteria. In exceptional circumstances they may be upgraded by three further criteria: large effect size, all plausible confounders would act to reduce the effect size, and evidence of a dose‐response effect ([Guyatt 2008](#CD009818-bbs2-0041){ref-type="ref-list"})

### Subgroup analysis and investigation of heterogeneity {#CD009818-sec3-0016}

We performed a subgroup analysis based on whether the participants were ART experienced or ART naive.

### Sensitivity analysis {#CD009818-sec3-0017}

Several studies had unclear risk of bias due to unclear reporting on allocation concealment, but this was not adequate to prompt a sensitivity analysis based on the trial quality.

Results {#CD009818-sec1-0005}
=======

Description of studies {#CD009818-sec2-0008}
----------------------

### Results of the search {#CD009818-sec3-0018}

We performed electronic literature searches up to 26 May 2016. We identified a total of 1007 records, which we screened by title/abstract. We identified 35 potentially eligible studies and obtained the full‐text articles of these studies. We excluded 10 studies, which we listed along with their reasons for exclusion in the \'[Characteristics of excluded studies](#CD009818-sec2-0023){ref-type="sec"}\' table. Twenty‐five trials met the inclusion criteria of the review. We have presented the study selection process in a PRISMA flow diagram ([Figure 1](#CD009818-fig-0001){ref-type="fig"}).

![Study flow diagram](nCD009818-AFig-FIG01){#CD009818-fig-0001}

### Included studies {#CD009818-sec3-0019}

See the \'[Characteristics of included studies](#CD009818-sec2-0022){ref-type="sec"}\' and [Table 3](#CD009818-tbl-0003){ref-type="table"}, which further describe the populations and interventions in the included trials.

###### Details of the interleukin‐2 intervention regimen

  ------------ -------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------
  **Number**   **Trial ID**                                                   **Follow‐up duration**                                          **Dosing regimen for interleukin‐2 (IL‐2)**                                                                                                                                                             **Comparisons**                                                                                                                                                **Outcomes**                                 **ART experienced or naive**

  1            [Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}        16 months                                                       Dose: 2 doses (4.5 and 7.5 miu)\                                                                                                                                                                        ART not specified                                                                                                                                              Viral load\                                  ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   CD4 cell count                               
                                                                                                                                              Duration: twice daily for 5 days every 8 weeks                                                                                                                                                                                                                                                                                                                                                                      

  2            [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}       7 years                                                         Dose: 4.5 miu\                                                                                                                                                                                          ART not specified                                                                                                                                              Opportunistic infections\                    Not specified
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Death from any cause\                        
                                                                                                                                              Duration: twice daily, 6 cycles                                                                                                                                                                                                                                                                                                                                        Adverse events                               

  3            [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}       7 years                                                         Dose: 7.5 miu\                                                                                                                                                                                          ART not specified                                                                                                                                              Opportunistic infections\                    Not specified
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Death from any cause\                        
                                                                                                                                              Duration: twice daily, 3 cycles                                                                                                                                                                                                                                                                                                                                        Adverse events                               

  4            [Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}      28 weeks                                                        Dose: 1 miu\                                                                                                                                                                                            Indinavir, stavudine, and lamivudine                                                                                                                           CD4 cell count\                              ART naive
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: daily for 5 days/week every alternate week for 3 months                                                                                                                                                                                                                                                                                                                                                   

  5            [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}       12 months                                                       Dose: 12 miu\                                                                                                                                                                                           ART not specified                                                                                                                                              CD4 cell count\                              ART experienced
                                                                                                                                              Route: intravenous\                                                                                                                                                                                                                                                                                                                                                    Viral load\                                  
                                                                                                                                              Duration: for 3, 4, or 5 days every 8 weeks for 6 cycles                                                                                                                                                                                                                                                                                                               Adverse events and serious adverse events\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     AIDS defining complex                        

  6            [Caggiari 2001](#CD009818-bbs2-0005){ref-type="ref-list"}      12 months                                                       Dose: 6 miu\                                                                                                                                                                                            2 nucleoside reverse transcriptase inhibitors (NRTIs) or 2 NRTIs and indinavir                                                                                 CD4 cell count\                              ART naive
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: from days 1 to 5 and days 8 to 12 of a 28‐day cycle for 6 cycles                                                                                                                                                                                                                                                                                                                                          

  7            [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}          12 months                                                       Dose: 1 miu\                                                                                                                                                                                            Zidovudine + didanosine + zalcitabine                                                                                                                          CD4 cell count\                              ART experienced
                                                                                                                                              Route: subcutaneous and intravenous\                                                                                                                                                                                                                                                                                                                                   Adverse events\                              
                                                                                                                                              Duration: Group A: 12 miu daily for 5 days every 8 weeks (27 participants)\                                                                                                                                                                                                                                                                                            Viral load\                                  
                                                                                                                                              Group B: 1 miu per cycle in equal divided doses in day 1 and 3 every 8 weeks (58 participants)                                                                                                                                                                                                                                                                         Opportunistic infections                     

  8            [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}         48 weeks                                                        Dose: 7.5 miu\                                                                                                                                                                                          ART not specified                                                                                                                                              CD4 cell count\                              ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load\                                  
                                                                                                                                              Duration: 6 cycles every 12 hours for 5 days every 8 weeks                                                                                                                                                                                                                                                                                                             Adverse events                               

  9            [Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"}         12 months                                                       Dose: 7.5 miu\                                                                                                                                                                                          ART not specified                                                                                                                                              CD4 cell count\                              Not specified
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: 3 cycles for 5 days every 8 week                                                                                                                                                                                                                                                                                                                                                                          

  10           [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}        12 months                                                       Dose: 9.6 miu\                                                                                                                                                                                          Saquinavir, lamivudine, and zidovudine                                                                                                                         CD4 cell count\                               ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load\                                  
                                                                                                                                              Duration: 5 cycles were given. One cycle was given every 6 weeks over a period of 52 weeks.\                                                                                                                                                                                                                                                                           Opportunistic infections                     
                                                                                                                                              Treatment group A : subcutaneous administered daily in cycles consisting of 5 days.\                                                                                                                                                                                                                                                                                                                                
                                                                                                                                              Treatment group B: subcutaneous administered at a dose of 9.6 miu daily whenever CD4 counts dropped to below 1.25 fold of individual\'s baseline value                                                                                                                                                                                                                                                              

  11           [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}       24 weeks with outcomes measured at weeks 1, 6, 12, 18, and 24   Dose: 4.5 miu\                                                                                                                                                                                          2 nucleoside analogues and one PI                                                                                                                              CD4 cell count\                              Not specified
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load\                                  
                                                                                                                                              Duration: every 6 weeks for 4 cycles, every 12 hours for 5 days                                                                                                                                                                                                                                                                                                        Adverse events\                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ART experienced                              

  12           [Kelleher 1998](#CD009818-bbs2-0012){ref-type="ref-list"}      48 weeks                                                        Dose: 12 miu\                                                                                                                                                                                           ART included nucleoside analogues such as lamivudine                                                                                                           CD4 cell count\                              ART experienced 
                                                                                                                                              Route: intravenous\                                                                                                                                                                                                                                                                                                                                                    Viral load                                   
                                                                                                                                              Duration: Group A: 12.6 miu as continuous intravenous infusions for 5 days every 8 weeks for 6 cycles. Group B (IL‐2 linked to polyethylene glycol plus ART):\                                                                                                                                                                                                                                                      
                                                                                                                                              subcutaneous injections on days 1 and 3 of each 8‐week cycles                                                                                                                                                                                                                                                                                                                                                       

  13           [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}        14 months                                                       Dose: 18 miu\                                                                                                                                                                                           ART included didanosine, zidovudine, zalcitabine, or stavudine                                                                                                 CD4 cell count\                              Not specified
                                                                                                                                              Route: intravenous\                                                                                                                                                                                                                                                                                                                                                    Plasma HIV RNA                               
                                                                                                                                              Duration: daily for 5 days every other month for 6 cycles from month 0 to 10                                                                                                                                                                                                                                                                                                                                        

  14           [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}      6 months                                                        Dose: 1.2 miu, and then increased by 0.3 miu every 2 weeks for 6 months until a participant experienced grade 2 or greater toxicity.\                                                                   ART not specified                                                                                                                                              CD4 cell count\                               ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load\                                  
                                                                                                                                              Duration: once daily for 2 weeks                                                                                                                                                                                                                                                                                                                                       Adverse events                               

  15           [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}          14 months                                                       Dose: 12 miu and 3 miu\                                                                                                                                                                                 Zidovudine (600 mg/day) plus didanosine (400 mg/day)                                                                                                           CD4 cell count\                              ART naive
                                                                                                                                              Route: 12 miu intravenous and 3 miu subcutaneous\                                                                                                                                                                                                                                                                                                                      Viral load\                                  
                                                                                                                                              intravenously (12 miu/day, N = 22) or subcutaneously (3 miu/m² twice daily, N = 24) for 5 days, or 2 miu/m² intravenous bolus, N = 22) administered every 2 months from week 2 to week 50 (7 cycles).                                                                                                                                                                  Adverse events                               

  16           [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}          18 months                                                       Dose: 5 miu\                                                                                                                                                                                            ART included lamivudine (300 mg/day), stavudine (60 to 80mg/day) and indinavir (2400 mg/day)                                                                   CD4 cell counts\                             ART naive or naive to PIs alone
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load\                                  
                                                                                                                                              Duration: twice daily for a 5 day cycle given every 4 weeks for the first 3 cycles and then subsequently every 8 weeks for the next 7 cycles                                                                                                                                                                                                                           AIDS defining events                         

  17           [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}         24 weeks                                                        Dose: escalating doses of 1.5 miu, 4.5 miu, 7.5 miu\                                                                                                                                                    ART not specified                                                                                                                                              CD4 cell counts .\                           Both naive and experienced participants were included in the study.
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: twice daily for 5 consecutive days every 8 weeks                                                                                                                                                                                                                                                                                                                                                          

  18           [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}     48 weeks                                                        Dose: 3 miu\                                                                                                                                                                                            ART was either 2 nucleoside reverse transcriptase inhibitor  and one PI or at least one non nucleoside reverse transcriptase inhibitor                         CD4 cell count\                              ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load\                                  
                                                                                                                                              Duration: administered as a single subcutaneous injection at days 1 to 5 and 8 to 12 of a 4‐week cycle, for a total of 3 cycles                                                                                                                                                                                                                                        Adverse events                               

  19           [Marchetti 2004](#CD009818-bbs2-0019){ref-type="ref-list"}     48 weeks                                                        Dose: 3 miu\                                                                                                                                                                                            ART not specified                                                                                                                                              CD4 cell count                               ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                              Duration: administered at day 1 to 5 and 8 to 12 for 10 weeks                                                                                                                                                                                                                                                                                                                                                       

  20           [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}     84 weeks                                                        Dose: Group A 9 miu and Group B 7.5miu\                                                                                                                                                                 Received ART alone, 2 nucleosides and a PI                                                                                                                     CD4 cell count\                              Not specified 
                                                                                                                                              Route: intravenous and subcutaneous\                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: Group A: intravenous infusions 5 days every 8 weeks.\                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                              Group B: subcutaneous injections 7.5 miu twice daily for 5 days every 8 weeks                                                                                                                                                                                                                                                                                                                                       

  21           [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}   24 weeks                                                        Dose: Group A 1.5 miu, Group B 4.5 miu, and Group C 7.5 miu\                                                                                                                                            ART not specified                                                                                                                                              CD4 cell count\                               ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: twice daily for 5 days, every 8 weeks for three cycles 8‐weekly                                                                                                                                                                                                                                                                                                                                           

  22           [Stellbrink 2002](#CD009818-bbs2-0022){ref-type="ref-list"}    601 days                                                        Dose: 9 miu\                                                                                                                                                                                            ART consisting of stavudine 30 to 40 mg twice daily, and lamivudine 150 mg twice daily, nelfinavir 750 mg 3 times daily and saquinavir 600 mg 3 times daily.   CD4 cell count\                              ART naive
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: once daily (with an option to switch to 4.5 miu twice daily) for 5 consecutive days per cycle administered at 6‐weekly intervals                                                                                                                                                                                                                                                                          

  23           [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}      12 months                                                       Dose: 3 regimens of IL‐2\                                                                                                                                                                               2 NRTIs and saquinavir                                                                                                                                         CD4 cell count\                              ART experienced
                                                                                                                                              Route: intravenous and subcutaneous\                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration:differed by group see details below\                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                              Group A: 12 miu by continuous intravenous infusion followed by subcutaneous 7.5 miu twice a day for 5 days every 8 weeks for the remaining 4 cycles.\                                                                                                                                                                                                                                                               
                                                                                                                                              Group B: subcutaneous 7.5 miu twice a day for 5 days every 8 weeks for 6 cycles.\                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                              Group C: subcutaneous 3 miu twice a day every 4 weeks                                                                                                                                                                                                                                                                                                                                                               

  24           [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}         12 months                                                       Dose: 7.5 miu\                                                                                                                                                                                          Nucleosides analogue reverse transcriptase inhibitor and either a non‐nucleosides analogue reverse transcriptase inhibitor or PI                               CD4 cell count\                              ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: Group A: 7.5 miu twice daily for 5 days versus placebo plus ART.\                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                              Group B: 7.5 miu twice a day for 5 days                                                                                                                                                                                                                                                                                                                                                                             

  25           [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}        24 weeks                                                        Dose: 1 miu\                                                                                                                                                                                            2 nucleoside reverse transcriptase inhibitors                                                                                                                  CD4 cell count\                              ART experienced
                                                                                                                                              Route: subcutaneous\                                                                                                                                                                                                                                                                                                                                                   Viral load                                   
                                                                                                                                              Duration: once daily                                                                                                                                                                                                                                                                                                                                                                                                
  ------------ -------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------

Abbreviations: ART antiretroviral therapy; IL‐2 Interleukin 2; NRTI nucleoside reverse transcriptase inhibitors; PI protease inhibitor

#### Study design and setting {#CD009818-sec4-0005}

We included 25 parallel‐design RCTs in the review ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}; [Caggiari 2001](#CD009818-bbs2-0005){ref-type="ref-list"}; [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}; [Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"}; [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Kelleher 1998](#CD009818-bbs2-0012){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Marchetti 2004](#CD009818-bbs2-0019){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}; [Stellbrink 2002](#CD009818-bbs2-0022){ref-type="ref-list"}; [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}; [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}; [Vogler 2004)](#CD009818-bbs2-0025){ref-type="ref-list"}.

Eleven trials were conducted in academic centres in the USA ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"}; [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}; [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}). The other 14 included trials were conducted in Argentina ([Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}), France ([Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}), Italy ([Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}; [Caggiari 2001](#CD009818-bbs2-0005){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Marchetti 2004](#CD009818-bbs2-0019){ref-type="ref-list"}; [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}), Australia ([Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Kelleher 1998](#CD009818-bbs2-0012){ref-type="ref-list"}), Germany ([Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}; [Stellbrink 2002](#CD009818-bbs2-0022){ref-type="ref-list"}), and Thailand ([Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}).

#### Participants {#CD009818-sec4-0006}

All participants were HIV‐positive adults either ART experienced or who were commenced on ART during the trial, with CD4 cell counts of at least 50 cells/mm³. The number of participants per trial ranged from nine participants ([Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"}), to 4111 participants ([Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}).

#### Interventions {#CD009818-sec4-0007}

In all included trials, participants in the intervention group received IL‐2 and ART, while those in the control group received ART alone. The dose of IL‐2 and the ART regimen varied across the included trials. Some trials compared doses of either 4.5 miu of IL‐2 , 7.5 miu of IL‐2 with ART, or different subgroups of both doses with the control group ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}). Some trials had three trial arms that compared different routes of administration, including subcutaneous versus intravenous administration with the control group (ART alone) ([Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}). Other included trials had three trial arms that compared IL‐2, a control group, and different modified forms of IL‐2, such as polyethylene glycol (PEG) modified IL‐2 ([Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Kelleher 1998](#CD009818-bbs2-0012){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}), and granulocyte stimulating factor‐modified IL‐2 ([Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}), and prednisone‐modified IL‐2 ([Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}).

#### Outcomes {#CD009818-sec4-0008}

Of the outcomes of interest in this Cochrane Review, the included trials reported the following outcomes: all‐cause mortality, change in CD4 cell, viral load, opportunistic infections, and adverse effects. However, none of the included trials reported on adherence.

### Excluded studies {#CD009818-sec3-0020}

After considering the full‐text articles, we excluded 10 potentially eligible studies that did not meet our inclusion criteria. We have provided the reasons for excluding these trials in the \'[Characteristics of excluded studies](#CD009818-sec2-0023){ref-type="sec"}\' table.

Risk of bias in included studies {#CD009818-sec2-0009}
--------------------------------

We have provided a graphical summary of the \'Risk of bias\' assessment results ([Figure 2](#CD009818-fig-0002){ref-type="fig"}; [Figure 3](#CD009818-fig-0003){ref-type="fig"}).  

![\'Risk of bias\' graph: review authors\' judgements about each \'Risk of bias\' item presented as percentages across all included trials](nCD009818-AFig-FIG02){#CD009818-fig-0002}

![\'Risk of bias\' summary: review authors\' judgements about each \'Risk of bias\' item for each included trial](nCD009818-AFig-FIG03){#CD009818-fig-0003}

### Allocation {#CD009818-sec3-0021}

#### Random sequence generation {#CD009818-sec4-0009}

There was adequate sequence generation in 11 of the 25 included trials ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}). There was high risk of selection bias in [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}. The remaining 13 included trials poorly reported the method of sequence generation.

#### Allocation concealment {#CD009818-sec4-0010}

More than half of included studies did not report allocation concealment clearly and were judged as having unclear risk of bias. One study, [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}, had high risk of allocation concealment bias due to the manner in which participant selection was conducted. .

### Blinding {#CD009818-sec3-0022}

The included trials were open label trials with no blinding of participants. However, all of the reported outcome measures are objective. Therefore we judged each of the included trials as at low risk of bias regarding blinding.

### Incomplete outcome data {#CD009818-sec3-0023}

We considered the following trials to have a low risk of attrition bias with low or minimal loss to follow‐up: [Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}; [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Kelleher 1998](#CD009818-bbs2-0012){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Marchetti 2004](#CD009818-bbs2-0019){ref-type="ref-list"}; [Stellbrink 2002](#CD009818-bbs2-0022){ref-type="ref-list"}; [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}; and [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}. There was high risk of attrition bias in [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"} and [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}. Five trials had unclear risk of attrition bias ([Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}; [Caggiari 2001](#CD009818-bbs2-0005){ref-type="ref-list"}; [Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"}; [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}; [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}).

### Selective reporting {#CD009818-sec3-0024}

All included trials were at low risk of selective reporting bias. The trials reported all outcomes that they described in the methods in the results.

### Other potential sources of bias {#CD009818-sec3-0025}

We identified other potential sources of bias in the following three trials ([Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}). In [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}, there was potential for both detection bias or performance bias due to the fact that the IL‐2 group were hospitalized for five to six days longer than the control group. However, as the outcomes reported are considered objective (i.e. CD4 count and viral load) the potential risk is probably low. [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"} had more monitoring in the IL‐2 group than in the control group, which caused a potential for detection bias and performance bias since some adverse effects could be subjective. There was a high risk of performance bias in [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"} due to differential treatment. Participants who were randomized to the continuous intravenous high dose and subcutaneous high dose groups received the first two cycles of IL‐2 as inpatients and the following cycles on an outpatient basis, whereas participants in the low dose and control groups were followed up as outpatients from the beginning of the trial.

Effects of interventions {#CD009818-sec2-0010}
------------------------

See: [Table 1](#CD009818-tbl-0001){ref-type="table"}

See [Table 1](#CD009818-tbl-0001){ref-type="table"}.

### Primary outcomes   {#CD009818-sec3-0026}

#### All‐cause mortality {#CD009818-sec4-0011}

Eight trials reported on all‐cause mortality ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}). Trials reported mortality at six months ([Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}), 12 months ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}), 13 months ([Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}), 14 months ([Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}), 20 months ([Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}), and seven years ([Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}). [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"} and [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"} had more than two trial arms, which we did not include in the pooled analysis. Therefore, we pooled results from six trials ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}) (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.80 to 1.17; 6 trials, 6565 participants, *high certainty evidence*; [Analysis 1.1](#CD009818-fig-00101){ref-type="fig"}; [Figure 4](#CD009818-fig-0004){ref-type="fig"}). There was no significant difference in the test for subgroup differences looking at ART experienced participants and others (ART naive or experienced or unclear ART status). We also did not find any significant subgroup differences with trials that reported the outcome at seven years and those that reported the outcome at less than 24 months.

![](nCD009818-AFig-FIG04){#CD009818-fig-0004}

### Secondary outcomes   {#CD009818-sec3-0027}

#### Change in CD4 cell count {#CD009818-sec4-0012}

Twenty‐one trials reported on change in CD4 cell count: ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}; [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}; [Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"}; [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}; [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}; [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}; [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}).

We did not pool the results because the included trials reported either means or median values differently (see [Table 4](#CD009818-tbl-0004){ref-type="table"} which describes the different reporting on CD4 count changes by the included trials).

###### Effect of intervention: change in CD4 count

  ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Increase in CD4 cell count with statistically significant difference**                 

  [Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}\                                 The average difference change in CD4 cell count between the IL‐2 group and control group was 217.1 cells/mm³ (95% CI 188.6 to 245.5; P \< 0.001) measured at 12 months.
  (at 12 months follow‐up)\                                                                
  n = 511                                                                                  

  [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}\                                   Median CD4 cell count increases of 359 and 44 cells/mm³ and a decline of 46 cells/mm³ in the cyclical continuous intravenous IL‐2, subcutaneous IL‐2, and ART alone group, respectively, over 12 months (P \< 0.0001 for each intergroup comparison).
  (at 12 months follow‐up)\                                                                
  n = 115                                                                                  

  [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}\                                  The median increase in CD4 count at 12 months was 279 cells/mm³ in the IL‐2 group compared with 50 cells/mm³ in the control (P \< 0.001).
  (at 12 months follow‐up)\                                                                
  n = 82                                                                                   

  [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}\                                The mean per cent increase in CD4 cell counts was 24.5% for IL‐2 recipients compared to a mean per cent decrease of 30.5% for control participants (P \< 0.005).
  n = 81                                                                                   

  [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}\                                 The median CD4 cell counts increased from 363 to 485 (+ 33.6% standard deviation) in the IL‐2 group Group A (P \< 0.01) and from 358 to 462 (+ 29.1%) in Group B (P \< 0.01) and from 350 to 375 (+ 6.9% in the control group (not significant), respectively.
  (at 12 months follow‐up)\                                                                
  n = 64                                                                                   

  [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}\                                The median increase in CD4 cells at week 24 was significantly higher in the IL‐2 group than in the control group (65 versus 18 cells/mm³; P \< 0.0001).
  (at 24 weeks, that is 6 months follow‐up)\                                               
  n = 72                                                                                   

  [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}\                                 There was an increase in the mean (± SE) CD4 count from 428 ± 25 cells/mm³ at baseline to 916 ± 128 in the IL‐2 group, compared to a decreased from 406 ± 29 cells/mm^3^ to 349 ± 41 cells/mm³ in the control group (P \< 0.001).
  (at 12 months follow‐up)\                                                                
  n = 60                                                                                   

  [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}\                               The percentage increase in CD4 count from baseline of 3.59% in the IL‐2 group compared to 1.33% in the control group (P \< 0.001).
  (at 26 weeks follow‐up)\                                                                 
  n = 115                                                                                  

  [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}\                                   The median increase in CD4 count from baseline at 56 weeks was 564 cells/mm³ (P \> 0.0001), 105 cells/mm³ (P = 0.58), and 676 cells/mm³ (P = 0.0002) in the subcutaneous (SC), polyethylene glycol modified, and intravenous (IV) IL‐2 group respectively, compared to 55 cells/mm³ in the control group
  (at 56 weeks follow‐up)\                                                                 
  n = 94                                                                                   

  [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}\                                   The median increase in CD4 count from baseline at week was 865 cells/mm³ in the IL‐2 group compared to 262 cells/mm³ in the control group (P \< 0.00001).
  (at 74 weeks follow‐up)\                                                                 
  n = 118                                                                                  

  [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}\                                  The mean increase in CD4 count from baseline at week 24 of 27 cells/mm³ (P = 0.105), 105 cells/mm³ (P = 0.006), and 492 cells/mm³ (P \< 0.001) in the 1.5, 4.5, and 7.5 miu dose groups of IL‐2. Overall 14 out of 36 (41%) of the IL‐2 group and 3 out of 37 (8%) of the controls had a magnitude increase of ≥ 1000 cells/mm³.
  (at 24 weeks follow‐up)\                                                                 
  n = 73                                                                                   

  [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}\                              IL‐2 treated participants had mean absolute CD4 T cell counts (S.E) significantly increase at the end of the IL‐2 treatment (week 48) from 147 (18) cells/mm³ at baseline to 298 (43.3) cells/mm³ (P=0001). The control participants also had a significant increase was observed 16 weeks 228 (29) cells/mm³ (P = 0.002).
  (48 weeks follow‐up)\                                                                    
  n = 22                                                                                   

  [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}\                              Reported median increases of CD4 cell count were 459, 312, and 102 cells/mm³ in the intravenous, SC Il‐2, and control groups respectively at 48 weeks (P \< 0.001 for both).
  (at 48 weeks follow‐up)\                                                                 
  n = 159                                                                                  

  [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}\                                  Reported a mean increase in CD4 count from baseline of 452 cells/mm^3^ in the IL‐2 group compared to 135 cells/mm^3^ in the control group (P \< 0.05).
  (at 12 months follow‐up)\                                                                
  n = 19                                                                                   

  [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}\                            Reported an increase in the time weighted mean CD4 cell count 252 x 10^6^ cells/mm³ over 24 weeks for the overall scIL‐2 group compared with 42 x 10^6^ cell/mm³.
  n = 82                                                                                   

  **Increase in CD4 cell count but statistical significance not reported in the trials**   

  [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}\                                Six trials measured at 1 year; median CD4 increase of 206 versus 21 cells/mm³ in the IL‐2 group versus the control group and reported an average median increase of 109 more in the IL‐2 group more than the control group over the entire 7 years (95% CI 40 to 60 over 6 years)
  (at 12 months follow‐up)\                                                                
  (at 6 years follow‐up)\                                                                  
  n = 4111                                                                                 

  [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}\                                Six trials measured at 1 year; median CD4 increase of 131 versus 32 cells/mm³ in the IL‐2 group versus the control group over 12 months and reported an average median increase of 53 more in the IL‐2 group more than the control group over the entire 7 years (95% CI 40 to 60 over 6 years)
  (at 12 months follow‐up)\                                                                
  n = 1695                                                                                 

  [Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"} (at 12 months follow‐up)\         Four participants treated with HAART plus 3 cycles of intermittent IL‐2 had an increase in median absolute CD4+ T cell count from 529 cells/mm³ (range: 502 to 738 cells/mm³) at enrolment to 1995 cells/mm³ (range: 1112 to 3064 cells/mm³; 268% increase) after 12 months of treatment (Figure 1A). Five participants treated with HAART alone had an increase in median CD4+ T cell count from 580 cells/mm³ (range: 416 to 662 cells) at enrolment to 712 cells/mm³ (range: 667 to 1160 cells/mm³; 52% increase) after 12 months of treatment
  n = 9                                                                                    

  **No significant increase in CD4 cell count**                                            

  [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}\                                 Mean change in CD4 count in the IL‐2 group and the control group was 40 and −1 respectively
  (at 24 weeks)\                                                                           
  n = 115                                                                                  

  [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}\                               Reports that there was a progressive increase in circulating CD4 cells, determined at the beginning of each IL‐2 cycle, was observed in all participants receiving ART plus IL‐2, in comparison with those receiving ART alone but gave the values for the within subgroup variation
  n = 61                                                                                   

  [Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}\                               No significant difference between changes in CD4 counts in both groups
  (at 6 months follow‐up)\                                                                 
  n = 22                                                                                   
  ---------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ART: antiretroviral therapy; ESPIRIT: Evaluation of Subcutaneous Proleukin in a Randomised International Trial; IL‐2: interleukin‐2; SILICAAT: subcutaneous recombinant human interleukin‐2 in HIV‐infected patients low CD4 counts under active antiretroviral therapy

##### Significant increase in CD4 cell count with IL‐2 {#CD009818-sec5-0001}

Fifteen trials reported a significant increase in CD4 cell count in the group assigned to IL‐2 treatment ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}; [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}; [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}).

##### Increase in CD4 cell count but statistical significance not reported {#CD009818-sec5-0002}

Five trials provided results for a relative increase in CD4 count in the groups receiving IL‐2. [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"} reported this outcome at seven years; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"} and [Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"} reported at six months; [Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"} and [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"} reported this at 84 weeks. However, these trials did not provide further details of whether the difference was statistically significant.

##### No significant increase in CD4 cell count {#CD009818-sec5-0003}

Two trials reported that there was no significant difference in the CD4 cell count between groups over 24 weeks, [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"} and [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}; however in the [Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"} trial the lack of difference depended on the dosing of IL‐2 with higher doses resulting in a significant difference in a dose‐response manner.

#### Proportion of participants with undetectable viral load at any time point {#CD009818-sec4-0013}

##### Plasma viral load less than 50 copies/mL {#CD009818-sec5-0004}

Seven trials reported on viral load of less than 50 copies/mL ([Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}; [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}). None of the included trials found any significant difference between the two groups irrespective of the time when the viral load was measured. Overall, in the pooled analysis, there was no significant difference in the proportion of participants with a viral load of less than 50 copies/mL by the end of the trials (RR 0.97, 95% CI 0.81 to 1.15; 5 trials, 805 participants, *high certainty evidence*; [Analysis 1.2](#CD009818-fig-00102){ref-type="fig"}; [Figure 5](#CD009818-fig-0005){ref-type="fig"}).

![](nCD009818-AFig-FIG05){#CD009818-fig-0005}

**Plasma viral load level less than 500 copies/mL**

Four trials reported on plasma viral load of less that 500 copies/mL ([Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}; [Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}). None of the included trials found any significant difference between the two groups in viral load of less than 500 copies/mL irrespective of the time when the viral load was measured. The overall results did not show any significant difference in the two groups (RR 0.96, 95% CI 0.82 to 1.12; 4 trials, 5929 participants, *high certainty evidence*; [Analysis 1.3](#CD009818-fig-00103){ref-type="fig"}; [Figure 6](#CD009818-fig-0006){ref-type="fig"}).

![](nCD009818-AFig-FIG06){#CD009818-fig-0006}

##### Undetectable viral loads {#CD009818-sec5-0005}

In [Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}, participants in both groups had HIV load levels below detection limit at the end of the study. [Caggiari 2001](#CD009818-bbs2-0005){ref-type="ref-list"} reported undetectable viral loads in six out of seven participants both the IL‐2 and ART only group. [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"} did not report any difference in the mean viral load in any of the study arms. In [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}, there were no significant differences between the groups in serial measurements of the plasma viral load or p24 antigen concentration during the 12 months of treatment.

##### Other viral load measurements {#CD009818-sec5-0006}

Six included trials found no significant difference in viral load ([Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}; [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}).

#### Opportunistic infections {#CD009818-sec4-0014}

Seven included trials reported the incidence of opportunistic infections ([Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}; [Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}; [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}). Overall there was no significant difference between the two groups (RR 0.79, 95% CI 0.55 to 1.13; 7 trials, 6141 participants, *low certainty evidence*; [Analysis 1.4](#CD009818-fig-00104){ref-type="fig"}; [Figure 7](#CD009818-fig-0007){ref-type="fig"}).
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#### Adherence {#CD009818-sec4-0015}

None of the included trials reported on adherence.

#### Adverse events {#CD009818-sec4-0016}

Nine included trials reported on adverse events ([Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}; [de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}; [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}; [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}; [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}; [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}; [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}).

##### GRADE 3 or higher adverse events {#CD009818-sec5-0007}

In [Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}, a total of 203 participants receiving IL‐2 and 186 participants in the control group had a grade 4 adverse event. In [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}, a total of 203/849 participants receiving IL‐2 and 186/846 participants in the control group had a grade 4 adverse event. [Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"} reported grade 3 or higher adverse events in 20/39 participants in the IL‐2 group and in 7/43 adverse events in the control group (RR 3.13, 95% CI 1.50 to 6.63). [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"} reported grade 3 adverse events in 10/56 participants (18%) in the IL‐2 group and in 9/59 (15%) of the control group while grade 4 adverse events were 1 (2%) and 3 (5%) respectively. [Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"} reported that severe adverse effects, such as aspartate transaminase deficiency, were reported in 2/26 of the participants in the control group and 16 participants (25%), 2 participants (5%), and 4 participants (9%), in the subcutaneous, PEG‐modified, and intravenous IL‐2 groups respectively. Severe neutropenia (less than 1 x 10^9^/mL) was also seen in 2/26 (8%) participants in the control group and 9 participants (8%), 2 participants (9%), 3 participants (4.5%) in the subcutaneous, PEG‐modified, and intravenous IL‐2 groups. [Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"} reported that grade 3 or 4 adverse effects were noted in 34/53 participants (64%) in the IL‐2 group compared to 12/56 participants (22%) in the control group (P \< 0.001).

In [Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}, both IL‐2 arms were associated with significantly more grade 3 or 4 clinical toxic effects usually associated with IL‐2 treatment (with values of 30%, 53%, and 67% for 57, 58, and 59 participants) in the ART only, intravenous IL‐2 group, and subcutaneous IL‐2 group respectively. [Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"} reported episodes of severe toxicities, neutropenia, and orthostatic blood pressure respectively in 2/5 participants compared to 0/4 in the control participants. [Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"} reported no statistical significant difference between both groups in grade 3 or worse adverse effects (P ≥ 0.12). By the end of the trial at 24 weeks, two grade 4 events had occurred: one case of grade 4 hypertriglyceridaemia, one case of agitation in the ART plus IL‐2 group, and none in the control. Overall there were greater adverse effects in those participants receiving IL‐2 (RR 1.47, 95% CI 1.10 to 1.96; six trials, 6291 participants, *moderate certainty evidence*; [Analysis 1.5](#CD009818-fig-00105){ref-type="fig"}; [Figure 8](#CD009818-fig-0008){ref-type="fig"}).
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##### GRADE 2 or lower adverse events {#CD009818-sec5-0008}

In [Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}, grade 2 or lower adverse events were reported in 43/56 participants in the IL‐2 group and in 47/59 of the control group. [Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"} reported that all participants receiving IL‐2 experienced at least one mild‐to‐moderate side‐effect, mainly constitutional symptoms such as fever, fatigue, malaise, and myalgias. [Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"} reported lower than grade 3 events in a total of 11 participants. Mild constitutional symptoms, such as fever (grade 1 to 2), fatigue, and myalgia were experienced by 10/12 participants receiving IL‐2, a reversible localized erythematous nodule at the site of injection was observed in 11/12 participants.

Discussion {#CD009818-sec1-0006}
==========

Summary of main results {#CD009818-sec2-0011}
-----------------------

We identified 25 trials that met our inclusion criteria. The number of participants in the included trials varied from nine to 4111 participants. Interleukin‐2 (IL‐2) doses and the duration of follow‐up varied across the included trials. We judged the risk of bias due to methodological quality of the included studies to be low. There was no significant difference in mortality whether IL‐2 was added to the ART regimen or not (*high certainty evidence*). There was a significant increase in CD4 cell count in the IL‐2 group in most of the included trials (*high certainty evidence*). There was no statistically significant difference between viral load in both groups for measures less than 50 copies/mL or 500 copies/mL in most trials (*high certainty evidence*). IL‐2 probably causes an increase in adverse effects, particularly grade 3 or 4 adverse effects (*moderate certainty evidence*). Most of the included trials reported similar adverse events, neutropenia, and myalgia were most commonly reported. There is probably no difference in the incidence of opportunistic infections in the IL‐2 and control groups (*low certainty evidence*). Adherence was not reported in any of the included trials.

Overall completeness and applicability of evidence {#CD009818-sec2-0012}
--------------------------------------------------

We conducted a comprehensive search and included all relevant trials regardless of whether they reported the reviews outcomes of interest. Most included trials excluded participants who were previously on immunomodulators or steroids, or with an autoimmune disease, or with malignancy requiring them to be on immunomodulators. The trials were conducted in different settings: including high‐ and middle‐income countries. However, there is no plausible biological reason why the findings may not be applicable to low‐income settings.

Quality of the evidence {#CD009818-sec2-0013}
-----------------------

We assessed the certainty of the evidence using the GRADE methodology, and presented the basis for the judgements in a \'Summary of findings\' table. The overall certainty of evidence on the effects of  IL‐2  as an adjunct to ART for reducing morbidity and mortality in HIV‐infected adults individuals can be described as high, which means that we are confident in this result and further research is unlikely to change the direction of the effect. This finding was consistent across all the included trials that reported on the outcome. In addition, IL‐2 increases the CD4 cell count significantly and there is no difference in the proportion of participants with undetectable viral loads (*high certainty evidence*). IL‐2 probably does not cause any important difference in the rates of opportunistic infections (*low certainty evidence*). However, it probably causes increased grade 3 or 4 adverse effects (*moderate certainty evidence*).

Potential biases in the review process {#CD009818-sec2-0014}
--------------------------------------

We conducted a comprehensive search to ensure that we identified all relevant completed or ongoing studies. There were no language or publication restrictions. We also reduced the potential bias in the conduct of this review: two review authors independently screened the search output, extracted data, and assessed the methodological certainty of each included trial.

Agreements and disagreements with other studies or reviews {#CD009818-sec2-0015}
----------------------------------------------------------

The findings of this review are similar to those of a literature review by [Pett 2001](#CD009818-bbs2-0033){ref-type="ref-list"}, which showed that IL‐2 adjunctive therapy can significantly increase the CD4 pool of HIV‐positive participants compared to ART alone, however it has no significant effect on viral load, and has an increase in adverse effects, particularly grade 4 adverse effects in some trials and an acceptable adverse effect profile in others. [Pett 2010](#CD009818-bbs2-0048){ref-type="ref-list"} concluded that IL‐2 adjunctive therapy confers no clinical benefit on HIV‐positive participants and has no place in the therapeutic treatment of HIV. Three trials that we included in this Cochrane Review were also included in [Pett 2010](#CD009818-bbs2-0048){ref-type="ref-list"} ([Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}; [Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}; [Stellbrink 2002](#CD009818-bbs2-0022){ref-type="ref-list"}).

The findings of this Cochrane Review differ from those of a pooled meta‐analysis of three randomized controlled trials (RCTs) by [Emery 2000](#CD009818-bbs2-0039){ref-type="ref-list"}, which showed a significant decrease in viral load in participants on IL‐2 with ART compared to ART alone. However, [Emery 2000](#CD009818-bbs2-0039){ref-type="ref-list"} also showed no significant increase in mortality and concluded that despite substantial improvement in CD4 cell count and viral load there was no significant improvement in clinical outcomes.

Authors\' conclusions {#CD009818-sec1-0007}
=====================

Implications for practiceInterleukin‐2 (lL‐2) as an adjunct to ART leads to increases in CD4 cell counts in HIV‐infected adults on ART. However, IL‐2 (irrespective of the dose or duration) has no important effect on other clinically important positive outcomes, such as mortality, viral load reduction, and rates of opportunistic infections, but probably results in increased adverse effects. Our findings do not support the use of IL‐2 as an adjunct to ART in HIV‐infected adults.

Implications for researchFurther RCTs on the use of IL‐2 as adjunct to ART in HIV‐infected adults are not justifiable based on the findings of this Cochrane review. However, further basic research may be helpful to explore why IL‐2 causes increases in CD4 cell count.

We thank colleagues at Cochrane South Africa, South African Medical Research Council, Cape Town for technical and methodological support, particularly Joy Oliver for conducting the literature searches for this review. Tamara Kredo is partly supported by the Effective Health Care Research Consortium. This Consortium and the editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this publication do not necessarily reflect UK government policy.
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**IDSearchHits**\#1MeSH descriptor: \[HIV Infections\] explode all trees8930\#2MeSH descriptor: \[HIV\] explode all trees2820\#3hiv or hiv‐1\* or hiv‐2\* or hiv1 or hiv2 or (hiv near infect\*) or (human immunodeficiency virus) or (human immunedeficiency virus) or (human immune‐deficiency virus) or (human immuno‐deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (acquired immuno‐deficiency syndrome) or (acquired immune‐deficiency syndrome) or (acquired immun\* deficiency syndrome) (Word variations have been searched)16171\#4MeSH descriptor: \[Lymphoma, AIDS‐Related\] this term only23\#5MeSH descriptor: \[Sexually Transmitted Diseases, Viral\] this term only25\#6\#1 or \#2 or \#3 or \#4 or \#516256\#7MeSH descriptor: \[Antiretroviral Therapy, Highly Active\] this term only1161\#8MeSH descriptor: \[Anti‐HIV Agents\] explode all trees3013\#9MeSH descriptor: \[Antiviral Agents\] this term only3778\#10MeSH descriptor: \[AIDS Vaccines\] this term only371\#11anti hiv or antiretroviral\* or anti retroviral\* or AIDS vaccin\*7521\#12\#7 or \#8 or \#9 or \#10 or \#1111280\#13\#6 and \#127996\#14MeSH descriptor: \[Interleukin‐2\] explode all trees848\#15\"interleukin 2\":ti,ab or IL2:ti,ab or IL‐2:ti,ab aldesleukin:ti,ab or proleukin:ti,ab or \"interleukin II\":ti,ab or interleukin2:ti,ab or \"interleukine 2\":ti,ab (Word variations have been searched)1526\#16\#14 or \#151794\#17\#13 and \#16144

**Date: 26 May 2016**

**SearchQueryItems found**[\#8](#8)Search (\#3 AND \#4 AND \#7)[634](634)[\#7](#7)Search (\#5 OR \#6)[69303](69303)[\#6](#6)Search (interleukin 2\[tiab\] OR interleukin2\[tiab\] OR IL2\[tiab\] OR IL‐2\[tiab\] OR aldesleukin\[tiab\] OR proleukin\[tiab\] OR interleukin II\[tiab\] OR interleukine 2\[tiab\])[62977](62977)[\#5](#5)Search interleukin‐2\[mh\][36542](36542)[\#4](#4)Search (randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized \[tiab\] OR placebo \[tiab\] OR drug therapy \[sh\] OR randomly \[tiab\] OR trial \[tiab\] OR groups \[tiab\]) NOT (animals \[mh\] NOT humans \[mh\])[3285304](3285304)[\#3](#3)Search (\#1 AND \#2)[99540](99540)[\#2](#2)Search (antiretroviral therapy, highly active\[MeSH\] OR anti‐retroviral agents\[MeSH\] OR antiviral agents\[MeSH:NoExp\] OR ((anti\[tiab\]) AND (hiv\[tiab\])) OR antiretroviral\*\[tiab\] OR ((anti\[tiab\]) AND (retroviral\*\[tiab\])) OR HAART\[tiab\] OR ((anti\[tiab\]) AND (acquired immunodeficiency\[tiab\])) OR ((anti\[tiab\]) AND (acquired immuno‐deficiency\[tiab\])) OR ((anti\[tiab\]) AND (acquired immune‐deficiency\[tiab\])) OR ((anti\[tiab\]) AND (acquired immun\*\[tiab\]) AND (deficiency\[tiab\]))[157998](157998)[\#1](#1)Search (HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tiab\] OR hiv‐1\*\[tiab\] OR hiv‐2\*\[tiab\] OR hiv1\[tiab\] OR hiv2\[tiab\] OR hiv infect\*\[tiab\] OR human immunodeficiency virus\[tiab\] OR human immunedeficiency virus\[tiab\] OR human immuno‐deficiency virus\[tiab\] OR human immune‐deficiency virus\[tiab\] OR ((human immun\*\[tiab\]) AND (deficiency virus\[tiab\])) OR acquired immunodeficiency syndrome\[tiab\] OR acquired immunedeficiency syndrome\[tiab\] OR acquired immuno‐deficiency syndrome\[tiab\] OR acquired immune‐deficiency syndrome\[tiab\] OR ((acquired immun\*\[tiab\]) AND (deficiency syndrome\[tiab\])) OR \"sexually transmitted diseases, Viral\"\[MeSH:NoExp\])[344877](344877)
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**No.QueryResults**\#11\#3 AND \#9 AND \#10318\#10\'interleukin 2\'/syn OR interleukin2:ab,ti OR \'aldesleukin\'/syn OR \'proleukin\'/syn OR il2 OR \'il+2\'/syn OR \'interleukin ii\'/syn OR \'interleukine 2\'117687\#9\#4 NOT \#81615894\#8\#5 NOT \#75350278\#7\#5 AND \#61470137\#6\'human\'/de OR \'normal human\'/de OR \'human cell\'/de17154813\#5\'animal\'/de OR \'animal experiment\'/de OR \'invertebrate\'/de OR \'animal tissue\'/de OR \'animal cell\'/de OR \'nonhuman\'/de6820415\#4\'randomized controlled trial\'/de OR \'randomized controlled trial\' OR random\*:ab,ti OR trial:ti OR allocat\*:ab,ti OR factorial\*:ab,ti OR placebo\*:ab,ti OR assign\*:ab,ti OR volunteer\*:ab,ti OR \'crossover procedure\'/de OR \'crossover procedure\' OR \'double‐blind procedure\'/de OR \'double‐blind procedure\' OR \'single‐blind procedure\'/de OR \'single‐blind procedure\' OR (doubl\* NEAR/3 blind\*):ab,ti OR (singl\*:ab,ti AND blind\*:ab,ti) OR crossover\*:ab,ti OR cross+over\*:ab,ti OR (cross NEXT/1 over\*):ab,ti1811081\#3\#1 AND \#2140652\#2\'human immunodeficiency virus vaccine\'/exp OR \'human immunodeficiency virus vaccine\' OR \'human immunodeficiency virus vaccine\':ab,ti OR \'anti human immunedeficiency\':ab,ti OR \'anti human immunodeficiency\':ab,ti OR \'anti human immuno‐deficiency\':ab,ti OR \'anti human immune‐deficiency\':ab,ti OR \'anti acquired immune‐deficiency\':ab,ti OR \'anti acquired immunedeficiency\':ab,ti OR \'anti acquired immunodeficiency\':ab,ti OR \'anti acquired immuno‐deficiency\':ab,ti OR \'anti hiv\':ab,ti OR antiretrovir\*:ab,ti OR \'anti retroviral\':ab,ti OR \'anti retrovirals\':ab,ti OR \'anti retrovirus\':ab,ti OR haart:ab,ti OR \'aids vaccine\':ab,ti OR \'aids vaccines\':ab,ti OR \'anti human immunodeficiency virus agent\'/exp OR \'anti human immunodeficiency virus agent\' OR \'anti human immunodeficiency virus agent\':ab,ti OR \'antiretrovirus agent\'/exp OR \'antiretrovirus agent\' OR \'antiretrovirus agent\':ab,ti OR \'highly active antiretroviral therapy\'/exp OR \'highly active antiretroviral therapy\' OR \'highly active antiretroviral therapy\':ab,ti196031\#1\'human immunodeficiency virus infection\'/exp OR \'human immunodeficiency virus infection\'/de OR \'human immunodeficiency virus infection\' OR \'human immunodeficiency virus\'/exp OR \'human immunodeficiency virus\'/de OR \'human immunodeficiency virus\' OR \'human immunodeficiency virus:ab,ti\' OR hiv:ab,ti OR \'hiv‐1\':ab,ti OR \'hiv‐2\':ab,ti OR \'human immunodeficiency virus\':ab,ti OR \'human immunedeficiency virus\':ab,ti OR \'human immune‐deficiency virus\':ab,ti OR \'human immuno‐deficiency virus\':ab,ti OR \'acquired immunodeficiency syndrome\':ab,ti OR \'acquired immuno‐deficiency syndrome\':ab,ti OR \'acquired immune‐deficiency syndrome\':ab,ti OR \'acquired immunedeficiency syndrome\':ab,ti446717

Search strategy: HIV AND (\"interleukin‐2\" OR \"interleukin 2\" OR aldesleukin OR proleukin OR \"interleukin II\") \| Interventional Studies \| received from 11/14/2014 to 05/26/2016

###### Interleukin‐2 versus control

  Outcome or subgroup title                                                 No. of studies   No. of participants   Statistical method                 Effect size
  ------------------------------------------------------------------------- ---------------- --------------------- ---------------------------------- ---------------------
  [1 All‐cause mortality](#CD009818-fig-00101){ref-type="fig"}              6                6565                  Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.80, 1.17\]
  1.1 ART experienced                                                       2                626                   Risk Ratio (M‐H, Random, 95% CI)   1.05 \[0.16, 7.11\]
  1.2 ART naive or not specified                                            4                5939                  Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.80, 1.17\]
  [2 HIV RNA levels \< 50 cells/mL](#CD009818-fig-00102){ref-type="fig"}    5                805                   Risk Ratio (M‐H, Random, 95% CI)   0.97 \[0.81, 1.15\]
  [3 HIV RNA levels \< 500 cells/mL](#CD009818-fig-00103){ref-type="fig"}   4                5929                  Risk Ratio (M‐H, Random, 95% CI)   0.96 \[0.82, 1.12\]
  [4 Opportunistic infections](#CD009818-fig-00104){ref-type="fig"}         7                6141                  Risk Ratio (M‐H, Random, 95% CI)   0.79 \[0.55, 1.13\]
  4.1 ART experienced                                                       2                97                    Risk Ratio (M‐H, Random, 95% CI)   0.30 \[0.05, 1.86\]
  4.2 ART naive or not specified                                            5                6044                  Risk Ratio (M‐H, Random, 95% CI)   0.81 \[0.56, 1.19\]
  [5 Adverse events (grade 3 or 4)](#CD009818-fig-00105){ref-type="fig"}    6                6291                  Risk Ratio (M‐H, Random, 95% CI)   1.47 \[1.10, 1.96\]

![Analysis\
Comparison 1 Interleukin‐2 versus control, Outcome 1 All‐cause mortality.](nCD009818-CMP-001-01){#CD009818-fig-00101}

![Analysis\
Comparison 1 Interleukin‐2 versus control, Outcome 2 HIV RNA levels \< 50 cells/mL.](nCD009818-CMP-001-02){#CD009818-fig-00102}

![Analysis\
Comparison 1 Interleukin‐2 versus control, Outcome 3 HIV RNA levels \< 500 cells/mL.](nCD009818-CMP-001-03){#CD009818-fig-00103}

![Analysis\
Comparison 1 Interleukin‐2 versus control, Outcome 4 Opportunistic infections.](nCD009818-CMP-001-04){#CD009818-fig-00104}

![Analysis\
Comparison 1 Interleukin‐2 versus control, Outcome 5 Adverse events (grade 3 or 4).](nCD009818-CMP-001-05){#CD009818-fig-00105}

Characteristics of included studies \[ordered by study ID\] {#CD009818-sec2-0022}
===========================================================

[Abrams 2002](#CD009818-bbs2-0001){ref-type="ref-list"}MethodsOpen‐label randomized controlled trial (RCT)ParticipantsEligibility criteria\
HIV‐positive.Adults (18 years or older).CD4 cell count of at least 300 cells/mm³.Receiving or initiating combination antiretroviral therapy (ART) at the time of randomization.\
Exclusion criteria\
Pregnancy.AIDS‐defining illness.Malignancy requiring chemotherapy.Use of systemic corticosteroid, hydroxyurea, or any other immunomodulator therapy within 4 weeks before randomization.Autoimmune disease.Breastfeeding.Any central nervous system (CNS) abnormality requiring anti‐seizure medication.\
The trial included a total of 511 (256 in the interleukin group and 255 in the control group) HIV‐1 infected adults\
Most participants were men (88.5%), white (69.3%), and had sex with a person of the same sex (76.7%).Median CD4 cell count at randomization was 536 cells/mm³ (302 to 1591 cells/mm³).InterventionsIntervention group: intermittent administration of 2 doses (4.5 and 7.5 miu) of subcutaneous plus antiretroviral treatment (ART)\
Control group: ART alone.OutcomesViral load.CD4 cell count.NotesThe trial was conducted in the USA.\
Duration of follow‐up: minimum of 12 months. Median duration of follow‐up was 16.2 months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used permuted block randomization with stratification by the CPCRA unit.Allocation concealment (selection bias)Low riskThe trial obtained random allocation of participants by calling the CPCRA Statistical Centre.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskLess than 15% of the participants were excluded from the final analysis or lost to follow‐up, and it was by intention‐to‐treat (ITT) analysis.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of bias from other sources.[Abrams 2009a](#CD009818-bbs2-0002){ref-type="ref-list"}MethodsOpen‐label RCTParticipantsEligibility criteria: HIV‐infected adult\
Exclusion criteria: not specifiedInterventionsIntervention group: 3 cycles and a dose of 7.5 miu of IL‐2 twice daily plus ART\
Control group: ART alone .OutcomesCD4 cell count.Viral load.Opportunistic infections.Death from any cause.Adverse events.NotesThe trial was conducted in the USA. The median duration of follow‐up was 7.0 years.\
Ths trial was funded and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial stratified randomization by individual clinical site.Allocation concealment (selection bias)Low riskThe central coordinating facility prepared all randomizations schedules.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe analysis was based on an ITT principle and less than 15% were lost to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other forms of bias.[Abrams 2009b](#CD009818-bbs2-0003){ref-type="ref-list"}MethodsOpen‐label RCTParticipantsEligibility criteria: HIV‐positive adults with CD4 cell count between 50 and 299 cells/mm³\
Exclusion criteria: not specifiedInterventionsIntervention group: 1 cycle of a dose of 4.5 miu twice daily for 5 consecutive days\
Control group: ART aloneOutcomesCD4 cell count.Viral load.Opportunistic infections.Death from any cause.Adverse events.NotesThe trial was conducted in the USA. The median duration of follow‐up was 7.6 years.\
The NIAID provided regulatory sponsorship, and Chiron, and subsequently Novartis.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial stratified randomization by individual clinical site.Allocation concealment (selection bias)Low riskThe central co‐ordinating facility prepares all randomization schedules.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe analysis was based on an ITT principle and less than 15% were lost to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other forms of bias.[Amendola 2000](#CD009818-bbs2-0004){ref-type="ref-list"}MethodsOpen‐label RCTParticipants22 HIV‐infected adults (12 males and 10 females)\
Inclusion criteria\
HIV‐infected adults \> 18 years of age.Asymptomatic.CD4 cell count \> 400 to 600 cells/mm³.Viral load \> 5000 copies/mL.\
Exclusion criteria\
Prior exposure to antiretrovirals, immunomodulators, corticosteroids.Hepatitis B and C infection.Patients with autoimmune disease.InterventionsThe participants were enrolled in 3 randomized groups.\
Six participants (group 1) were treated with ART (Indinavir 2400 mg/day; stavudine 60 ± 80 mg/day; lamivudine 300 mg/day).Eight participants (group 2) were treated with ART and IL‐2 (aldesleukin, 1000 000 U/day ) subcutaneously, 5 days/week at alternative weeks).Eight participants (group 3) received granulocyte colony‐stimulating factor (G‐CSF; filgrastim, 5 mg/kg per day, for 5 consecutive days) to stimulate hematopoietic progenitor cell mobilization before starting ART and rIL‐2.\
All participants were treated with ART for 1 month before receiving differentiated therapies (ART; ART 1rIL‐2; (G‐CSF) ART 1rIL‐2) for an additional 12/24 weeks.OutcomesCD4 cell count.Viral load.Level of peripheral mononuclear blood cell apoptosis.Expression of CD45RA and CD62L T naive cells and memory cells.NotesThe trial was conducted in Italy.\
Duration of follow‐up: 24 weeks.\
Outcomes were analysed at baseline, 12, and 24 weeks.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe whether this was done or not.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe whether this was done or not.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe study was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesUnclear riskWe do not have enough information from the trial to make a judgement.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskWe did not identify any other potential sources of bias.[Caggiari 2001](#CD009818-bbs2-0005){ref-type="ref-list"}MethodsParalell single centred RCTParticipants14 HIV‐infected adults\
Inclusion criteria\
ART naive.CD4 \> 200 cells/mm³.HIV viraemia \> 500 copies/mL.No previous IL‐2 therapy.At least 18 years of age.1000 granulocytes/mm³.\
Exclusion criteria\
Abnormal thyroid function and cardiovascular.Abnormal pulmonary and central nervous system involvement.InterventionsIntervention group: 6 miu of IL‐2 from days 1 to 5 and 8 to 12 of a 28 day cycle for 6 cycles plus ART(2 reverse transcriptase inhibitors and indinavir)\
Control group: ART aloneOutcomesCD4 cell count.Viral load.NotesThis trial was conducted in Italy.\
Duration of follow‐up: 12 months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThere was no mention of the specific method of sequence generation or randomization but in the discussion section it was stated that randomization was done to ensure comparability of both groupsAllocation concealment (selection bias)Unclear riskThere was no mention of the specific method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and not likely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesUnclear riskWe do not have enough information from the study to make a judgement.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskWe did not identify any other potential sources of bias.[Carr 1998](#CD009818-bbs2-0006){ref-type="ref-list"}MethodsRCTParticipants115 HIV‐infected adults\
Inclusion criteria\
HIV‐infected adults \> 18 years of age.CD4 lymphocyte count between 200 and 500 cells/mm³.Karnofsky score = 60.At least 2 months of continuous antiretroviral therapy (ART) at study initiation.No prior IL‐2 therapy.No AIDS‐defining illness.\
Exclusion criteria: not specifiedInterventionsThere were 3 trial arms\
Intravenous IL‐2 plus ART, 12,000,000 IU of IL‐2 daily for 5 days every eight weeks (27 participants).Subcutaneous PEG IL‐2 plus ART, 1,000,000 IU per cycle in equal divided doses in day 1 and 3 every eight weeks (58 participants).ART alone (30 participants).\
ART consisted of zidovudine + didanosine + zalcitabineOutcomesCD4 cell count.CD8 cell count.Adverse events.NotesThe trial was conducted in Australia.\
Duration of follow‐up: 12 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial not describe the method for sequence generation.Allocation concealment (selection bias)Unclear riskThe trial did not described the method for allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial authors analysed all participants included in the trial.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasHigh riskThere was a high risk of selection bias and detection bias. Participants were randomized on a 1:2:1 basis for the continuous intravenous IL‐2, PEG‐IL‐2 ( Polyethylene glycol ) modified IL‐2, and control groups respectively. The trial authors rationalized that the unequal randomization allowed for determination of the maximally tolerated dose significance levels of PEG IL‐2 as well as its efficacy. This was bound to cause selection bias. Secondly, IL‐2 participants were hospitalized the first 5 to 6 days of the cycle causing possible detection bias[Davey 2000](#CD009818-bbs2-0007){ref-type="ref-list"}MethodsMulticentred RCTParticipantsInclusion criteria: HIV‐infected adults\
Exclusion criteria: not specifiedInterventionsIntervention: 6 cycles of IL‐2, 7.5 miu + ART\
Control: ART aloneOutcomesCD4 cell count\
Viral load\
Adverse eventsNotesThe trial was conducted in the USA.\
Duration of follow‐up was 12 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial randomly assigned participants to treatment groups by a computer generated block randomization with block sizes of 4 for the first 2 blocks and subsequently block sizes of 2.Allocation concealment (selection bias)Low riskCentral randomization by a biostatistician who was not part of the data analysis.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskBiostatisticians were blinded from knowing which participants were in which treatment groups.Incomplete outcome data (attrition bias)   All outcomesLow riskIt is unlikely that there was attrition bias since \< 15% withdrew or were lost to follow‐up. There was no differential loss to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective outcome reporting.Other biasLow riskThere was no evidence of other potential sources of bias.[de Boer 2003](#CD009818-bbs2-0008){ref-type="ref-list"}MethodsMulti‐centred RCTParticipantsInclusion criteria\
Karnofsky performance score greater than or equal to 70.HIV‐positive participant aged 18 years and above.CD4 cell counts of between 100 to 300 cells/mm³.Prior use of stable ART regimen for at least 2 months before the trial.No AIDS defining illness except kaposi\'s Sarcoma or pneumocystis jirovecii pneumonia.\
Exclusion criteria: not specifiedInterventionsTreatment group: participants received intravenous recombinant IL‐2 12 miu/day for 3, 4, or 5 days + ART every 8 weeks for 6 cycles\
Control group: ART aloneOutcomesChange in CD4 cell count.Viral load.Adverse effects.AIDS defining illness.NotesThe trial was conducted in USA. Duration of follow‐up was 12 months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThere is likely to be a low risk of selection bias as participants were assigned in equal proportions of 1 to 4 treatments and participants were stratified by treatment centre.Allocation concealment (selection bias)Low riskRandomization was done centrally.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial addressed loss to follow‐up and was less than 15%.Selective reporting (reporting bias)Low riskThere was no evidence of potential reporting bias from selective reporting.Other biasLow riskThere was no evidence of other potential sources of bias.[Dybul 2002](#CD009818-bbs2-0009){ref-type="ref-list"}MethodsRCTParticipants9 participants\
Inclusion criteria\
HIV RNA level of \> 500 copies/mL.Documented HIV infection of\< 6 months with participant already on ART.Non‐reactive ELISA within 6 months of enrolment.participants with a history of symptoms or prior exposure to acute antiretroviral syndrome and a non reactive western blot within 6 months of enrolment.participants with a history of symptoms or prior exposure to acute antiretroviral syndrome and an indeterminate western blot within 6 months of enrolment.\
Exclusion criteria: not specifiedInterventionsTreatment group: intermittent IL‐2 administered subcutaneously in 3 cycles for 5 days every 8 week plus ART\
Control group: ART alone. regimen:\
stavudine 30 mg to 40 mg twice daily,\
lamivudine 150 mg twice daily, indinavir 800 mg twice dailyOutcomesCD4 cell count.Lymphocyte subsets including CD4+, CD45RO, CD3+, CD8+.NotesThis was a pilot study conducted in the USA. Duration of follow‐up: 12 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not provide any details.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide any details.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesUnclear riskWe do not have enough information from the trial to make a judgement.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskWe did not identify any other potential sources of bias.[Hengge 1998](#CD009818-bbs2-0010){ref-type="ref-list"}MethodsThis was a prospective RCTParticipantsThere was a total of 64 participants.\
Inclusion criteria\
Adult HIV‐positive participants with CD4 count between 200 to 500 cells/mm³.Normal haematological, hepatic, biliary, and renal function.Had been receiving stable ART (saquinavir, lamivudine, and zidovudine)\
Exclusion criteria: not specifiedInterventionsTreatment group A (22): ART plus subcutaneous IL‐2 administered at a dose of 9.6 miu daily in cycles consisting of 5 days. A total of 5 cycles were given. One cycle was given every 6 weeks over a period of 52 weeks.\
Treatment group B (22): ART plus subcutaneous IL‐2 administered at a dose of 9.6 miu daily whenever CD4 counts dropped to below 1.25 fold of individual\'s baseline value.\
Control group: ART alone\
participants were followed up for a duration of 12 monthsOutcomesChange in CD4 count.Proportion of people with undetectable viral load.Opportunistic infections.Adverse effectsNotesThe trial was conducted in Germany.\
Duration of follow‐up: 12 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskThere was no true randomization as controls were chosen from participants fulfilling the inclusion criteria who did not wish to experience the potentially adverse effects of lL‐2.\
Secondly, the trial authors did not describe the method of sequence generation.Allocation concealment (selection bias)High riskThere is unlikely to be allocation concealment based on the support for judgement for sequence generation above.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThere is unlikely to have been attrition bias as the trial excluded less than 15% of the participants.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting of outcomes.Other biasLow riskThere were no other potential sources of bias.[Katlama 2002](#CD009818-bbs2-0011){ref-type="ref-list"}MethodsMulticentred open label RCTParticipantsA total of 72 participants.\
Inclusion criteria\
18 years or older.CD4 cells counts 25‐200 cells/mm³.Viral load of \< 1000 copies/mL while receiving ART (2 nucleoside analogues and 1 protease inhibitor (PI)) for 3 months.\
Exclusion criteria: participants on cytotoxic chemotherapy or corticosteroids within 3 months prior to the trialInterventionsIntervention: 4.5 miu of IL‐2 administered subcutaneously plus ART every 6 weeks for 4 cycles, every 12 hours for 5 days\
Control: ART aloneOutcomesPlasma HIV RNA levels.CD4 and CD8 count.NotesThe trial was conducted in 18 clinical centres in France.\
Duration of follow‐up: 24 weeks.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial performed randomization of participants by using computer‐generated random numbers.Allocation concealment (selection bias)Low riskThe trial performed allocation centrally.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial authors used ITT for the primary outcome.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskWe did not identify any other potential sources of bias.[Kelleher 1998](#CD009818-bbs2-0012){ref-type="ref-list"}MethodsThis was a single centred pilot study which was planned as a pilot study of a multi‐centred RCT to be conducted.Participants18 participants consecutively enrolled into 3 groups\
Inclusion criteria\
Adults who had asymptomatic HIV infections.CD4 counts between 200 to 500 cells/mm³.Receiving nucleoside analogue ART regimen.\
Exclusion criteria: not specifiedInterventionsTreatment group A (IL‐2 plus ART only)\
IL‐2 at doses of 12.6 X 10^6^ U/day\
as continuous intravenous infusions for 5 days every 8 weeks for 6 cycles\
Treatment group B (IL‐2 linked to polyethylene glycol plus ART)\
Escalating doses of subcutaneous injections of IL‐ 2 on day 1 and 3 of each 8‐week cycle.\
Control group\
ART alone.\
Each group had 150 mg of lamivudine twice daily added to their regimen at 30 weeks.OutcomesCD4 cell counts.Viral loads.Responses to recall antigens.NotesThis was a multicentred trial conducted in Australia.\
Duration of follow‐up: 48 weeks***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of random sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial excluded less than 15% of the participants.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskWe did not identify any other potential sources of bias.[Kovacs 1996](#CD009818-bbs2-0013){ref-type="ref-list"}MethodsThis was a single‐centred RCTParticipantsA total of 60 participants were randomized\
Inclusion criteria\
HIV‐postive participants aged 18 years and older.No history of opportunistic infection.CD4 counts \> 200 cells/mm³.Not received corticosteroids or cytotoxic chemotherapy. participants who had not received any experiment al therapy in the preceding 4 weeks.\
Exclusion criteria: not specifiedInterventionsTreatment group: intravenous IL‐2 given at intermittent infusions of 18 miu plus ART\
Control group: ART alone consisting of zidovudine, zalcitabine, or stavudine with didanosineOutcomesViral load.CD4 cell count.NotesStudy was conducted in the USA.\
The duration of follow‐up was 14 months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskLess than 15% were lost to follow‐up and the trial authors described withdrawals.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskWe did not identify any other potential sources of bias.[Lalezari 2000](#CD009818-bbs2-0014){ref-type="ref-list"}MethodsMulticentred phase 2 RCTParticipantsA total of 115 participants\
Inclusion criteria\
HIV‐infected individuals on ART ( highly active antiretroviral therapy)CD4 cell count \< 300 cells/mm³.Viral load \< 500 copies/mL.ART experienced.\
Exclusion criteria: not specifiedInterventionsTreatment group (IL‐2 plus ART): 51 participants\
Low dose IL‐2 administered subcutaneously at 1.2 miu once daily for 6 months\
Control group: ART alone\
participants continued on their current regimen and received HAART aloneOutcomesCD4 cell counts.Adverse effects.Viral load.NotesThis trial was conducted in the USA.\
Duration of follow‐up: 26 weeks***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSequence generation was by block randomization stratified by study site.Allocation concealment (selection bias)Low riskThe trial authors used a central randomization process.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesHigh riskMore than 15% withdrew from the trial due to adverse effects and the trial authors did not analyse their results.Selective reporting (reporting bias)Low riskThere was no evidence of selective outcome reporting.Other biasLow riskThere was no evidence of any other sources of bias.[Levy 1999](#CD009818-bbs2-0015){ref-type="ref-list"}MethodsMulticentred an open label RCTParticipantsA total of 94 participants\
Inclusion criteria\
Participants aged 18 years and above.With asymptomatic HIV infection.ART naive.Also naive to corticosteroids, chemotherapy, and experimental therapy.CD4 counts between 250 to 550 cells/mm³.\
Exclusion criteria: not specifiedInterventionsPolyethylene‐glycol (PEG) modified IL‐2 administered as 2 miu intravenous bolus for 7 cycles from 2nd week to 50th week plus ARTControl group: ART alone.OutcomesProportion of people with 80% rise in CD4 count.Change in CD4 cell count.Viral load change from baseline to end of study.Adverse effects.NotesThis study was conducted in 14 university clinics in France.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of random sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThere was no evidence of incomplete outcome data. Less than 15% were lost to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting bias.Other biasLow riskThere was no evidence of other sources of bias.[Levy 2003](#CD009818-bbs2-0016){ref-type="ref-list"}MethodsThis was a prospective RCT.ParticipantsThere were a total of 118 participants\
Inclusion criteria\
Asymptomatic HIV participants who were either completely ART naive or naive to PIs alone.Were over 18 years of age.Had a CD4 cell count of between 200 to 550 cells/mm³.\
Exclusion criteria: not specifiedInterventionsTreatment group: ART started 4 weeks before plus subcutaneous IL‐2 administered at a dose of 5 miu twice daily for 5 days given every 4 weeks for the first 3 cycles and then subsequently every 8 weeks for the next 7 cycles.\
Control group: ART alone consisting of lamivudine (300 mg/day), stavudine (60 to 80mg/day), and indinavir (2400 mg/day).OutcomesAbsolute and percentage change in CD4 cell counts.Proportion of participants with at least a 50% rise in CD4 cell counts at weeks 72 to 74 from baseline.Viral load.AIDS defining events.Adverse effects.Adherence.NotesThis was a multicentred study conducted in 14 university clinics in France.\
Duration of follow‐up was 18 months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors did not describe the method of sequence generation. However, the trial authors mentioned that randomization was centralized and stratified according to ART status.Allocation concealment (selection bias)Low riskThe trial authors used a centralized method of randomization.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial excluded less than 15% (2 out of 118 participants) from the analysis. There was no differential loss to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other sources of bias.[Losso 2000](#CD009818-bbs2-0017){ref-type="ref-list"}MethodsStudy design was a prospective open‐labelled RCTParticipantsThere were a total of 73 participants\
Inclusion criteria\
HIV participants who had been on ART For greater than or equal to 7 days.Not pregnant with a Karnofsky performance score ≥ 80.Were over 18 years of age.Had a most recent CD4 cel count of \> 350 cells/mm³.\
Exclusion criteria\
History of or presence of AIDS defining illness.History of malignancy requiring systemic use of corticosteroids or immuno modulators within the prior 5 years.Autoimmune/inflammatory disease like Crohns disease.InterventionsTreatment group: subcutaneous IL‐2 given at escalating doses of 1.5 miu, 4.5 miu, 7.5 miu with ART given twice daily for 5 consecutive days every 8 weeks plus ART.Control group: ART alone.OutcomesProportion of participants with viral load ≤ 500 copies/mL.Mean change in CD4 cell count.Mean change in viral load.NotesThis was a multi‐centred trial conducted in 6 clinical centres in Buenos Aires, Argentina.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a stratified block randomization method, using blocks of 24 stratified according to ART history (naive or experienced) and clinical centres.Allocation concealment (selection bias)Low riskThe trial used a centralized method of randomization.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial excluded less than 15% (2 out of 73 participants) from the analysis. There was no differential loss to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasHigh riskThere was more monitoring in the treatment group compared to the control group.[Marchetti 2002](#CD009818-bbs2-0018){ref-type="ref-list"}MethodsOpen labelled parallel RCTParticipants22 participants were randomized:\
Inclusion criteria\
18 years and above.Immunological non‐responders (INRs), that is participants on ART showing failure to restore their circulating CD4 counts despite good control of HIV plasma viraemia and have received an ART regimen consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 PI for at least a year.Have HIV RNA load of \< 50 copies/mL for at least 6 months.\
Exclusion criteria\
Pregnant women.Active drug users (alcohol abusers).participants with cardiovascular and thyroid disorders.Previously treated with cytotoxic drugs or growth factors.participants who were previously not compliant with ART medication.InterventionsTreatment group (12): they were commenced on IL‐2 for a 4 week cycle for 3 cycles plus ART\
Control group (10): ART consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 PIOutcomesProportion of participants with undetectable viral load.Mean change in CD4 count.Change in CD8 count.Opportunistic infections.Adverse events.NotesThis trial was an explanatory trial conducted at the University of Milan, Italy.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial followed up all participants to the end of the trial, and even included those who were lost to follow‐up afterwards in the results.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting bias.Other biasLow riskThere was no evidence of other potential sources bias.[Marchetti 2004](#CD009818-bbs2-0019){ref-type="ref-list"}MethodsThis was a RCTParticipantsThere were a total of 15 participants\
Inclusion criteria\
Participants on ART showing failure to restore their circulating CD4 counts despite good control of HIV plasma viraemia and have received ART regimen consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 PI for at least a year.CD4 cell counts constantly less than or equal to 200 cells/mm³ and HIV RNA load of \< 50 copies/mL after 12 months of stable ART.\
Exclusion criteria\
Not specified.InterventionsTreatment group (8): participants received 3 cycles of low dose subcutaneous IL‐2 over a 48‐week period. Each cycle consisted of 3 miu IL‐2 administered at days of 1 to 5 and days 8 to 12 of a 10‐week duration plus ART\
Control group (7): ART aloneOutcomesPercentage change in CD4 count.Absolute change in CD4 count.NotesThis was a small immunological trial conducted to investigate the long‐term kinetics of CD4 and CD8 cells when low dose IL‐2 is administered in Milan, Italy.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThere was no loss to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting of outcomes.Other biasLow riskWe did not identify any other potential sources of bias.[Mitsuyasu 2007](#CD009818-bbs2-0020){ref-type="ref-list"}MethodsThis was a multi‐arm parallel RCTParticipantsThere were a total of 159 participants\
Inclusion criteria\
HIV‐positive participants without AIDS defining illness.ART naive or had been treated only reverse transcriptase inhibitors (RTI) and 1 PI for at least a year.CD4 cell counts constantly from 50 to 350 cells/mm³ and HIV RNA load of \< 50 copies/mL after 12 months of stable ART.\
Exclusion criteria\
Previous use of PIs or IL‐2 therapy.Cardiac disease.InterventionsTreatment group A (intravenous IL‐2 plus ART): received continuous infusions of IL‐2 at doses of 9 miu for 5 days every 8 weeks plus ART\
Treatment group B (subcutaneous IL‐2 plus ART): received subcutaneous injections of IL‐2 7.5 miu twice daily for 5 days every 8 weeks plus ART\
Control group: ART alone, 2 NRTIs, and a PIOutcomesChange in CD4 countChange in plasma viral levels.Adverse effects.All‐cause mortality.NotesThis was a multicentred trial conducted at 26 AIDS Clinical Trials Group (ACTG) sites in the USA.\
Duration of the trial was 84 weeks.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThere is likely to be a low risk of selection bias because although the trial authors did not describe the method of sequence generation, participants were randomized in proportions of 1:1:1 and stratified by participation in a previous trial ACTG 928 and nucleosides.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesHigh riskThe trial excluded more than 15% of participants from the analysis.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other potential sources of bias.[Ruxrungtham 2000](#CD009818-bbs2-0021){ref-type="ref-list"}MethodsMulticentred parallel RCTParticipantsInclusion criteria\
HIV‐infected adults.\
Exclusion criteria\
History of AIDS defining illness, malignancy needing treatment within the last 5 years, medical condition corticosteroids, or cytotoxic chemotherapy.InterventionsTreatment groups (A, B, and C): received 1.5 miu, 4.5 miu, and 7.5 miu of IL‐2 administered twice daily for 5 days, every 8 weeks for three cycles.\
Control groups: ART alone.OutcomesChange in CD4 count.Change in viral load.Proportion of undetectable viral load.NotesThis was a multi‐arm pragmatic trial conducted in Thailand.\
Duration of follow‐up was 24 weeks.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors did not clearly specify the method of random sequence generation but it appeared to be low risk. Randomization was stratified by clinical centre and ART treatment history, that is naive or pretreated.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesUnclear riskThe trial authors did not describe withdrawals or missing data.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other potential sources of bias.[Stellbrink 2002](#CD009818-bbs2-0022){ref-type="ref-list"}MethodsProspective RCTParticipantsThere were 56 participants.\
Inclusion criteria\
Asymptomatic HIV participants.Had a CD4 cel count of \> 350 cells/mm³.plasma viral load\> 400 copies/mL.Had seroconverted 12 months prior to entry.Aged between 18 to 70 years.\
Exclusion criteria\
History of AIDS defining illness ([Castro 1992](#CD009818-bbs2-0038){ref-type="ref-list"}).Malignancy needing treatment within the last 5 years.Medical condition corticosteroids.InterventionsTreatment group (27): ART plus recombinant subcutaneous IL‐2 at 9 MU (megaunits) once daily (with an option to switch to 4.5 MU twice daily) for 5 consecutive dayControl group (29): ART alone consisting of stavudine 30 to 40 mg twice daily, and lamivudine 150 mg twice daily, nelfinavir 750 mg 3 times daily, and saquinavir 600 mg 3 times daily.OutcomesChange in CD4 countChange in plasma viral levelsNotesThis was an open label RCT conducted in Germany. Mean follow‐up duration ranged from 582 ‐ 601 days.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not report the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not report the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial authors performed analysis was ITT and there were no losses to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other potential sources of bias.[Tambussi 2001](#CD009818-bbs2-0023){ref-type="ref-list"}MethodsThis was a phase 2 RCT.ParticipantsThere was a total of 61 participants.\
Inclusion criteria\
HIV‐infected adults with CD4 cell count of between 200 to 550 cells/mm³, plasma viral load \> 400 copies/mL.\
Exclusion criteria: not specifiedInterventionsTreatment arm A (high dose intravenous arm): ART plus 12 miu of IL‐2 by continuous intravenous infusion followed by subcutaneous 7.5 miu IL‐2 twice a day for 5 days every 8 weeks for the remaining 4 cycles.\
Treatment arm B (high dose subcutaneous arm): ART+subcutaneous 7.5 miu IL‐2 twice a day for 5 days every 8 weeks for 6 cycles.\
Treatment arm C (low dose arm): ART plus subcutaneous IL‐2 +3 miu twice a day every 4 weeks\
Control: ART aloneOutcomesChange in CD4 count.Change in plasma viral levels.Adverse effects.NotesThis was an phase 2 RCT conducted in Milan Italy. The duration of follow‐up was a 12 months.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not report the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not report the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial authors performed analysis by ITT principle and less than 15% of participants were lost to follow‐up.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasHigh riskThere were differential treatment participants in the 2 groups. Participants were followed up as outpatients in 1 group and as inpatients in the other group.[Tavel 2003](#CD009818-bbs2-0024){ref-type="ref-list"}MethodsThis was a double blinded randomized placebo controlled trialParticipantsThere were a total of 19 participants.\
Inclusion criteria\
HIV‐positive participants with a CD4 cell count ≥ 350 cells/mm³ ≤ 1 month before the trial.Had been stable on 2 nucleosides analogue reverse transcriptase inhibitor and either a non‐nucleoside analogue reverse transcriptase inhibitor or PI.\
Exclusion criteria\
History of AIDS defining illness.Malignancy requiring treatment during the preceding 5 years.Medical conditions requiring cytotoxic chemotherapy.InterventionsGroup A: subcutaneous IL‐2 (7.5 miu IL‐2 twice daily for 5 days) and placebo) plus ART\
Group B: IL‐2 (7.5 miu IL‐2 twice daily for 5 days) and 0.5 mg prednisone/kg/day for 7 days every 8 weeks plus ART\
Group C: 0.5 mg prednisone/ kg/day for 7 days every 8 weeks plus ART\
Group D: placebo orally for 7 days (1 cycle ) every 8 weeks plus ARTOutcomesViral loadChange in CD4 cell count.NotesThis study was conducted in the USA. Duration of follow‐up was 12 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesUnclear riskThere was no loss to follow‐up and ITT.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other potential sources of bias.[Vogler 2004](#CD009818-bbs2-0025){ref-type="ref-list"}MethodsThis was a phase 2 multi‐centred randomized open label trialParticipantsThere was a total of 115 participants\
Inclusion criteria\
HIV‐infected participants confirmed by serology, \> 18 years old.CD4 cell count of between 300 to 700 cells/mm³.Stable on single or dual nucleoside therapy for at least 2 months.No history of AIDS defining illness ([Castro 1992](#CD009818-bbs2-0038){ref-type="ref-list"})No IL‐2 treatment within the last 3 months.\
Exclusion criteria\
History of AIDS defining illness.Systemic malignancies, or cardiac disease, or untreated thyroid disease.Pregnant and breast feeding women, as well as asthmatic and autoimmune disease participants.Active opportunistic infection.No immunomodulating drugs, or cytotoxic chemotherapy, or systemic corticosteroids at least 4 weeks before trial.InterventionsTreatment group: self administered subcutaneous IL‐2 1 miu daily in 0.2 mL volume at rotating skin sites in combination with continued ART\
Control: ART alone.OutcomesViral load.Change in CD4 cell count.Adverse effects.Adherence.All‐cause mortality.NotesThis trial was conducted in the USA.\
The duration of follow‐up was 24 weeks.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding of participants and personnel (performance bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Blinding of outcome assessment (detection bias)   All outcomesLow riskThe trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding.Incomplete outcome data (attrition bias)   All outcomesLow riskThe trial excluded less than 15% from the analysis.Selective reporting (reporting bias)Low riskThere was no evidence of selective reporting.Other biasLow riskThere was no evidence of other potential sources of bias.[^1]

Characteristics of excluded studies \[ordered by study ID\] {#CD009818-sec2-0023}
===========================================================

StudyReason for exclusion[Bosch 2010](#CD009818-bbs2-0026){ref-type="ref-list"}Both the intervention and control group received interleukin‐2 (IL‐2)[Chun 1999](#CD009818-bbs2-0027){ref-type="ref-list"}This was a cross‐sectional study[Crespo 2008](#CD009818-bbs2-0028){ref-type="ref-list"}This was a cohort study[Jacobson 2002](#CD009818-bbs2-0029){ref-type="ref-list"}This was a study of interleukin‐12 (IL‐12) and not IL‐2[Kilby 2006](#CD009818-bbs2-0030){ref-type="ref-list"}Participants in the intervention group received both IL‐2 and a vaccine[Lafeuillade 2001](#CD009818-bbs2-0031){ref-type="ref-list"}Participants in the intervention group received both IL‐2 and interferon‐gamma[Martin 2005](#CD009818-bbs2-0032){ref-type="ref-list"}The study did not report any outcomes relevant to this review[Pett 2001](#CD009818-bbs2-0033){ref-type="ref-list"}This was a review of randomized controlled trials[Tavel 2010](#CD009818-bbs2-0034){ref-type="ref-list"}The study compared participants receiving no treatment, IL‐2 alone, or IL‐2 with antiretroviral treatment (ART)[Witzke 1998](#CD009818-bbs2-0035){ref-type="ref-list"}Here the comparison was between subcutaneous IL‐2 and ART and intravenous IL‐2 and ART. The control group was not relevant to this review[^2]

Jennifer Onwumeh and Charles Okwundu wrote the draft protocol and review, independently performed the study selection and data extraction. Tamara Kredo contributed to the protocol, gave input into the manuscript, analysis and the final review.
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Department for International Development, UK.Grant: 5242
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[^1]: Abbreviations: AIDS: acquired immunodeficiency virus; ART: antiretroviral therapy; CNS: central nervous system; PEG: polyethylene glycol; HIV: human immunodeficiency virus; ITT: intention to treat; IL‐2: interleukin‐2; NRTI: nucleoside reverse transcriptase inhibitors; PI: protease inhibitor; RCT: randomized controlled trial; USA: United States of America.

[^2]: Abbreviations: IL‐2: interleukin‐2.
